Rhode Island Senate Bill S2466

Rhode Island 2026 Regular Session

• Introduced: 2/6/26
• Refer: 2/6/26

Caption

Provides for fair pharmacy reimbursement from a pharmacy benefit manager, and also provides anti-discrimination prohibitions in regard to non-affiliated pharmacies or pharmacists.

Impact

If enacted, S2466 would significantly influence existing state insurance laws, particularly in how pharmacy benefit managers operate and interact with both affiliated and non-affiliated pharmacies. The bill mandates transparency in reimbursement practices and requires pharmacy benefit managers to provide necessary data to ensure compliance. This move is expected to empower non-affiliated pharmacists and ensure they can compete more effectively in the market, ultimately benefiting consumers through increased choices and potentially lower costs.

Summary

Bill S2466, introduced in the Rhode Island General Assembly, establishes provisions for fair pharmacy reimbursement practices. The bill specifically aims to prevent pharmacy benefit managers from reimbursing non-affiliated pharmacies at lower rates than affiliated ones. By promoting reimbursement parity, S2466 seeks to ensure that all pharmacies receive equal compensation for the same drugs or services, thus fostering a fairer competitive landscape within the pharmacy sector. The legislation is a response to longstanding concerns that non-affiliated pharmacies are often financially disadvantaged in comparison to their affiliated counterparts.

Contention

Notably, S2466 has become a focal point for debate regarding the balance of power between large pharmacy benefit managers and smaller, independent pharmacies. Supporters of the bill argue that it is essential for fairness and competition, enabling independent pharmacies to thrive. However, some stakeholders in the pharmacy industry have raised concerns about the potential for increased costs in the insurance system, as pharmacy benefit managers may pass on expenses associated with compliance to consumers. Consequently, the bill's stakeholders are closely monitoring its implications on both pharmacy operations and healthcare costs in Rhode Island.